On the stock market since 2013, it operates in the world of health and science. It has 260 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
The stock has been running stronger than the market lately.
Business Quality: Profit power and business quality trail similar companies in the sector.
Growth: Sales growth trails the sector average.
angles, checked one by one.
The 5 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Executive Buying: The trades send no strong signal of confidence.
An investor who bought at the very peak is down 66% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The company sells $125.6M a year; the problem isn’t sales — it’s costs running above that number.
There is $547.7M in the vault; even if every debt were paid off, $360.0M would remain.
The average analyst price target is $27.00 — 81% above today’s price.
A loss of $91.9M against $125.6M in annual sales.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 23/100.
The growth engine is running at low revs right now. Report-card grade: 38/100.
On our five-subject report card, XNCR sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: XNCR is a small company that closed last year at a loss. The road back to profit runs through spending discipline.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (42/100) says the stock isn’t cheap.